251 related articles for article (PubMed ID: 34001163)
1. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
[TBL] [Abstract][Full Text] [Related]
2. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
3. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
4. KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion.
Sabe H
Cell Commun Signal; 2023 May; 21(1):106. PubMed ID: 37158894
[TBL] [Abstract][Full Text] [Related]
5. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
[TBL] [Abstract][Full Text] [Related]
6. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
7. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
8. ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.
Hashimoto A; Hashimoto S
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834383
[TBL] [Abstract][Full Text] [Related]
9. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
11. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
12. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
13. Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y; Poggio M; Jin HY; Shi Z; Forester CM; Wang Y; Stumpf CR; Xue L; Devericks E; So L; Nguyen HG; Griselin A; Gordan JD; Umetsu SE; Reich SH; Worland ST; Asthana S; Barna M; Webster KR; Cunningham JT; Ruggero D
Nat Med; 2019 Feb; 25(2):301-311. PubMed ID: 30643286
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
15. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
16. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
17. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
[TBL] [Abstract][Full Text] [Related]
18. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
[TBL] [Abstract][Full Text] [Related]
19. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
20. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]